SCHEMBL12803632

SCHEMBL12803632

Cc1cc2cc(C#N)ccc2n1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 5/20 0.38
▸ CYP11B1 P15538 4/20 0.38
▸ CYP2A6 P11509 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ IMPDH2 P12268 1/20 0.34
▸ IMPDH1 P20839 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ ENPP3 O14638 1/20 0.34
▸ BRPF1 P55201 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ BRD1 O95696 1/20 0.34
▸ BRD9 Q9H8M2 1/20 0.34
▸ BRD7 Q9NPI1 1/20 0.34
▸ BRPF3 Q9ULD4 1/20 0.34
▸ CDC7 O00311 1/20 0.33
▸ ACLY P53396 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22939250 0.85 DHFR (0.38) CYP11B2CYP11B1CYP2A6ALDH1A1IMPDH2
SCHEMBL10053515 0.76 BRPF1 (0.45) CYP2A6ALDH1A1KDM4EGAAENPP3
SCHEMBL10054048 0.75 BRPF1 (0.50) CYP11B2CYP11B1CYP2A6ALDH1A1KDM4E
SCHEMBL12958608 0.75 CNR1 (0.38) CYP11B2CYP11B1CYP2A6ALDH1A1IMPDH2
SCHEMBL12968248 0.75 BRPF1 (0.44) CYP2A6ALDH1A1KDM4EGAABRPF1
SCHEMBL12958654 0.71 ENPP3 (0.39) CYP11B2CYP11B1IMPDH2IMPDH1ENPP3
SCHEMBL12803570 0.70 CDC7 (0.43) CYP2A6ALDH1A1IMPDH2IMPDH1KDM4E
SCHEMBL22004379 0.68 ACLY (0.46) CYP11B2CYP11B1ACLY
SCHEMBL29134584 0.68 CDC7 (0.39) CYP11B2CYP11B1ALDH1A1KDM4EGAA
SCHEMBL30704292 0.68 CDC7 (0.39) CYP11B2CYP11B1ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 — — US disclosed
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 — — US disclosed
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 — — US disclosed
WO-2012131031-A1 NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR H. LUNDBECK A/S (DK) 2012-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor CHRNG, CHRNA7, CHRNA2 CYP11B2 2215/4885CYP11B1 2119/4885CYP2A6 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback